New study analyzes Real-World data on immunotherapy for kidney cancer
NCT ID NCT05858749
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study looked at medical records from 494 adults with advanced kidney cancer to see how well first-line immunotherapy combinations work and what happens when patients switch to other treatments later. Researchers tracked how long patients stayed on each treatment, how they responded, and overall survival. The goal was to understand real-world effectiveness, not to test a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Headquarters
New York, New York, 10017, United States
Conditions
Explore the condition pages connected to this study.